CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Capecitabine +2 moredrug
Likely dose
Capecitabine 850 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00398320
NCT00398320Phase 2Completed
CompareCT.gov

A Phase II Study of Capecitabine, Oxaliplatin and Bevacizumab for Metastatic or Unresectable Neuroendocrine Tumors

Pamela L. Kunz·interventional·Posted Nov 10, 2006·Updated Mar 1, 2017

In Brief

A Phase 2 clinical trial evaluating Capecitabine, Oxaliplatin, and 1 other intervention for Neuroendocrine Tumors. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Given the lack of other viable treatment options for metastatic neuroendocrine tumors, contrasted with our positive anecdotal experience, and the relative tolerability of the treatment regimen for colorectal cancer patients, we propose a single-institution phase II trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 10, 2006
Enrollment StartNov 1, 2006
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 19.6 years ago

Interventions

Capecitabinedrug

850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle

Oxaliplatindrug

130 mg/m2 intravenously on day 1 of a 21 day cycle

Bevacizumabdrug

7.5mg/kg Intravenous on day 1 of a 21 day cycle